Inhibitory effects of phytochemicals on metabolic capabilities of CYP2D6*1 and CYP2D6*10 using cell-based models in vitro

被引：0
|
作者：
Qiang Qu
Jian Qu
Lu Han
Min Zhan
Lan-xiang Wu
Yi-wen Zhang
Wei Zhang
Hong-hao Zhou
机构：
[1] Institute of Clinical Pharmacology,
[2] Hunan Key Laboratory of Pharmacogenetics,undefined
[3] Xiangya Hospital,undefined
[4] Central South University,undefined
[5] Xiangya Hospital,undefined
[6] Central South University,undefined
[7] Institute of Life Sciences,undefined
[8] Chongqing Medical University,undefined
来源：
Acta Pharmacologica Sinica | 2014年 / 35卷
关键词：
CYP2D6; drug interaction; herbal medicine; coptisine; bilobalide; schizandrin; luteolin; puerarin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：685 / 696
页数：11
相关论文
共 50 条
  • [1] Inhibitory effects of phytochemicals on metabolic capabilities of CYP2D6*1 and CYP2D6*10 using cell-based models in vitro
    Qu, Qiang
    Qu, Jian
    Han, Lu
    Zhan, Min
    Wu, Lan-xiang
    Zhang, Yi-wen
    Zhang, Wei
    Zhou, Hong-hao
    ACTA PHARMACOLOGICA SINICA, 2014, 35 (05) : 685 - 696
  • [2] IN VITRO COMPARATIVE INHIBITORY PROFILES OF SEVERAL CYP2D6 INHIBITORS AND METABOLIC CAPABILITIES OF CYP2D6*1, CYP2D6*2, CYP2D6*10, AND CYP2D6*17 ON TRAMADOL METABOLISM
    Nahid, N.
    Kanumuri, S.
    Sharma, A.
    Wang, D.
    Johnson, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S74 - S75
  • [3] CYP2D6 genotypes in a Japanese population:: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10
    Nishida, Y
    Fukuda, T
    Yamamoto, I
    Azuma, J
    PHARMACOGENETICS, 2000, 10 (06): : 567 - 570
  • [4] Assessment of Activity Levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 Genes by Population Pharmacokinetics of Dextromethorphan
    Abduljalil, K.
    Frank, D.
    Gaedigk, A.
    Klaassen, T.
    Tomalik-Scharte, D.
    Jetter, A.
    Jaehde, U.
    Kirchheiner, J.
    Fuhr, U.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (05) : 643 - 651
  • [5] Is CYP2D6 phenotype predictable from CYP2D6 genotype?
    Kiss, Adam Ferenc
    Toth, Katalin
    Juhasz, Cintia
    Temesvari, Manna
    Paulik, Jozsef
    Hirka, Gabor
    Monostory, Katalin
    MICROCHEMICAL JOURNAL, 2018, 136 : 209 - 214
  • [6] CYP2D6 polymorphism in a Gabonese population:: contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype
    Panserat, S
    Sica, L
    Gérard, N
    Mathieu, H
    Jacqz-Aigrain, E
    Krishnamoorthy, R
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 47 (01) : 121 - 124
  • [7] Profile of the inhibitory effects of gefitinib in CYP2D6 variants in vitro
    Semba, Yurika
    Akiyoshi, Takeshi
    Hibino, Hideyuki
    Imaoka, Ayuko
    Ohtani, Hisakazu
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2020, 58 (10) : 539 - 542
  • [8] Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors
    Gressier, F.
    Verstuyft, C.
    Hardy, P.
    Becquemont, L.
    Corruble, E.
    JOURNAL OF NEURAL TRANSMISSION, 2015, 122 (01) : 35 - 42
  • [9] Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors
    F. Gressier
    C. Verstuyft
    P. Hardy
    L. Becquemont
    E. Corruble
    Journal of Neural Transmission, 2015, 122 : 35 - 42
  • [10] Frequencies of three CYP2D6 nonfunctional alleles (CYP2D6*3,*4, and*6), and the metabolic capacity of CYP2D6 in Northern Iranian Population (Mazandaran)
    Shiran, Mohammad R.
    Soteh, Mohammad B. Hashemi
    Merat, Fatemeh
    Sarzare, Fatemeh
    Salehifar, Ebrahim
    DRUG METABOLISM REVIEWS, 2010, 42 : 260 - 261
12345